DNA-PK inhibitors
US-9592232-B2 · Mar 14, 2017 · US
DNA-PK inhibitors for treatment of cancer
US9878993B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9878993-B2 |
| Application number | US-201615159378-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2016 |
| Priority date | Apr 24, 2012 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of potentiating a therapeutic regimen for the treatment of breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer or prostate cancer in a patient comprising the step of administering to said patient an effective amount of a compound selected from the group consisting of:
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9878993B2 cover?
- The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).